Cubist Pharmaceuticals Inc announced that they are set to acquire Optimer Pharmaceuticals Inc and Trius Therapeutics Inc as part of the company' goal to build up its antibiotics portfolio. The deal was tagged at US$1.62 billion. Cubist announced that they will pay Optimer shareholders US$10.75 per share in an upfront cash payment. Cubist also mentioned that they will pay an additional US$5 per share dependent on Optimer meeting sales objectives. Cubist said that for Trius, the company will pay US$13.50 per share in an upfront cash payment plus another US$2 dependent on Trius meeting sales targets.
"I don't think (Cubist) will create a ton of value out of (the Optimer deal), but I don't think it's going to wind up looking like a bad deal," Baird analyst Brian Skorney said. "The risk to me is that there is a little bit of overlap in terms of Trius' drug and Cubicin in terms of market opportunity in outpatient complicated skin infection."
With the acquisition, Cubist will gain a late stage Trius drug that is tagged to treat skin infections. For the Optimer deal, Cubic will gain the antibacterial Dificid.
Join the Conversation